Skip to main content
Fig. 4 | Respiratory Research

Fig. 4

From: Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics

Fig. 4

Efficacy of switching to mepolizumab from omalizumab by the presence or absence of comorbidities. *Pre-treatment refers to the 12 months prior to screening; †32-week study period refers to the time between first dose of mepolizumab and study conclusion, regardless of treatment discontinuation. Rate ratio reflecting annualised clinically significant exacerbation rate during 32-week study period compared with rate during pre-treatment period. MCID for ACQ-5 and SGRQ is 0.5 points and 4 points, respectively; error bars represent SE. ACQ Asthma Control Questionnaire, CI confidence interval, FEV1 forced expiratory volume in 1s, GERD gastroesophageal reflux disease, LS least squares, MCID minimum clinically important difference, NP nasal polyps, NSAID aspirin/non-steroidal anti-inflammatory drug, RR rate ratio, SE standard error, SGRQ St George's Respiratory Questionnaire

Back to article page